When to Evaluate for Renal Artery Stenosis
In a patient with steadily increasing blood pressure over the past year and normal kidney function, you should screen for renal artery stenosis (RAS) if specific high-risk clinical features are present, rather than routinely testing all patients with worsening hypertension.
High-Risk Clinical Features That Warrant RAS Evaluation
The 2025 AHA/ACC guidelines and ACR appropriateness criteria identify specific clinical scenarios where RAS screening is appropriate 1, 2:
Screen for RAS when any of these are present:
- Age-related patterns: New-onset hypertension after age 50, OR significant hypertension (diastolic >110 mmHg) in a young adult (<35 years)
- Severity markers: Resistant hypertension (uncontrolled on 3+ medications) or malignant/accelerated hypertension
- Acute deterioration: Sudden worsening of previously controlled blood pressure
- Medication response: Deterioration of kidney function after starting ACE inhibitors or ARBs
- Physical examination: Abdominal bruit over the renal arteries
- Associated conditions: Recurrent flash pulmonary edema without clear cardiac cause, or generalized atherosclerotic disease elsewhere (coronary, carotid, peripheral arterial disease)
Why Your Patient's Presentation Matters
Your patient has steadily increasing BP over one year with normal kidney function. This presentation alone does not automatically warrant RAS screening 2. The gradual progression over a year is less concerning than abrupt onset or sudden worsening. Normal kidney function also makes hemodynamically significant RAS less likely, though not impossible 3.
Key Decision Point:
Determine if your patient has any of the high-risk features listed above. If yes, proceed with screening. If no, optimize medical management first and reserve RAS evaluation for treatment failure or development of concerning features.
Diagnostic Approach When Screening Is Indicated
First-line imaging options (in order of preference based on kidney function) 2:
- CT angiography (CTA) - Excellent sensitivity/specificity; use if eGFR >30 mL/min (contrast-induced nephropathy risk is lower than previously thought)
- MR angiography (MRA) - Effective alternative; avoid gadolinium if eGFR <30 (NSF risk); can use non-contrast protocols
- Doppler ultrasound - Safe regardless of kidney function but operator-dependent; good initial screen
Treatment Implications Based on Current Evidence
The 2025 guidelines emphasize that medical therapy is the foundation of treatment for atherosclerotic RAS 1:
Standard Medical Management:
- Antihypertensive regimen including RAS blocker (ACE inhibitor or ARB)
- High-intensity statin
- Antiplatelet therapy
- Smoking cessation
- Diabetes control if applicable
Revascularization (angioplasty ± stenting) is reserved for:
- Progressively worsening kidney function despite medical therapy
- Recurrent flash pulmonary edema
- Fibromuscular dysplasia (younger patients, especially women; angioplasty alone without stenting may be curative) 1
Critical caveat: Multiple RCTs (including CORAL trial) showed no benefit of revascularization over medical therapy alone for blood pressure control or preventing cardiovascular events in most patients with atherosclerotic RAS 1, 4. The absence of severe albuminuria predicts better outcomes if revascularization is performed 1.
Common Pitfalls to Avoid
- Don't screen indiscriminately: RAS prevalence in general hypertensive population is only 0.5-5%; screening everyone with worsening BP leads to overdiagnosis 2
- Don't equate anatomic stenosis with renovascular hypertension: Finding RAS on imaging doesn't prove it's causing hypertension; only 0.1-5% of anatomic stenoses are hemodynamically significant 1
- Don't rush to revascularization: Even when RAS is found, medical therapy should be optimized first in most cases 1, 4